Objective To predict the main active ingredients,potential targets and molecular mechanisms of Yuan Zhi powder in treatment of dementia by using network pharmacology.Methods A database of chemical constituents of Yuan...Objective To predict the main active ingredients,potential targets and molecular mechanisms of Yuan Zhi powder in treatment of dementia by using network pharmacology.Methods A database of chemical constituents of Yuan Zhi powder was constructed by using databases and literatures.Potential targets were predicted by reverse molecular docking,and then a component-target network was constructed.The target network of Alzheimer's disease(AD)was mapped and analyzed to obtain the“active ingredient-AD target”network.The key targets were screened through network analysis.Finally,the rationality of the prediction was analyzed by comparing with the target reported in the literatures.Results There were180chemical constituents acting on the AD target,and the targets included three key targets(cyclooxygenase-2,muscarinic acetylcholine receptor M1,and muscarinic acetylcholine receptor M2)and an important target(acetylcholine esterase).Alzheimer's disease may be treated by regulating the activity of acetylcholine receptors and the binding toβ-amyloid protein,and its biological process may be concentrated in the acetylcholine receptor signal pathway,negative regulation of synaptic transmission and so on.Conclusion The fact that Yuan Zhi powder can treat AD is consistent with the characteristics of multi-components-multitargets-multiple pathways of traditional Chinese medicine.The important targets obtained from network analysis have a large proportion in literature research,so network analysis have some rationality.展开更多
Objective:To explore and verify the mechanism of Gan Dou Ling in improving liver fibrosis in Wilson disease(WD)by network pharmacology and copper loaded mice experiments.Methods:The main chemical components and corres...Objective:To explore and verify the mechanism of Gan Dou Ling in improving liver fibrosis in Wilson disease(WD)by network pharmacology and copper loaded mice experiments.Methods:The main chemical components and corresponding gene targets of each drug in Gan Dou Ling were obtained by using TCMSP database.The database of gene mutation and disease related gene was searched through the GeneCards database,DrugBank database,PharmGKB database and the DisGeNET database.After the intersection of drug and disease target genes.The STRING website was used to analyze the protein-protein interaction degree of target genes,and import the data to Cytoscape software 38.2 to analyze protein interaction network.The GO databases and KEGG databases were obtained in R language for enrichment analysis.On this basis,Masson staining were used to observe the degree of liver fibrosis in copper loaded mouse model,and the results of network pharmacological analysis were verified by Western Blot(WB).Results:A total of 108 drug disease intersection genes were analyzed by network pharmacology.Through PPI network analysis,JUN was found to be the key genes.The enrichment analysis of KEGG pathway showed that MAPK signal pathway was the important potential target pathways.Animal experiments showed that Gan Dou Ling could reduce liver fibrosis and inhibit the phosphorylation of P38,JNK and C-JUN in copper loaded mice.Conclusion:Gan Dou Ling may achieve the effect of treating WD liver fibrosis by inhibiting P38/JNK signaling pathway.展开更多
Short Retraction Notice The paper does not meet the standards of “Chinese Medicine ". This article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE&#...Short Retraction Notice The paper does not meet the standards of “Chinese Medicine ". This article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE's Retraction Guidelines. The aim is to promote the circulation of scientific research by offering an ideal research publication platform with due consideration of internationally accepted standards on publication ethics. The Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused. Editor guiding this retraction: Prof. Maythem Saeed (EiC of CM) The full retraction notice in PDF is preceding the original paper, which is marked "RETRACTED".展开更多
Objective:To evaluate the efficacy and safety of Shen Zhi Ling oral liquid(SZL)alone or combined with basic treatment in treating Alzheimer's Disease(AD).Methods:Databases including PubMed,the Cochrane Library,Emb...Objective:To evaluate the efficacy and safety of Shen Zhi Ling oral liquid(SZL)alone or combined with basic treatment in treating Alzheimer's Disease(AD).Methods:Databases including PubMed,the Cochrane Library,Embase,Web of science,China National Knowledge Infrastructure(CNKI),Wanfang Database and the Chinese Science and Technology Journal Database(VIP)were searched from inception to September 20,2020 to collect relevant randomized controlled trials(RCTs)comparing SZL with other nootropic drugs for AD.The primary clinical outcomes were scores of the Mini Mental State Examination(MMSE)and the Activities of Daily Living(ADL)during treatment.The secondary outcomes of our study included other neuropsychological scale scores including Rapid Verbal Retrieve(RVR),Digit Span(DS),Fuld Object-Memory Evaluation(FOM)and adverse events or reactions.Two authors searched and screened the literature independently,then extracted the data and evaluated the methodological quality by using the handbook of Cochrane Collaboration,and analyzed the data via the Review Manager 5.3 software.Results:In total,we included four studies,covering 217 participants.All studies were in a low methodological quality.The result of MMSE score,ADL score,RVR score,DS score and FOM score in the meta-analysis showed that no statistically significant difference(P>0.05)between the treatment groups and control groups,and the statistical heterogeneity of all meta-analyses was small(I2<50%).SZL was indicated no better than other nootropic drugs.Among the included studies,no study described adverse events.Conclusions:Considering the low quality of the included trials and the different levels of AD patients,we are unable to come to any conclusion about the efficacy and safety of SZL compared with other nootropic drugs.Moreover,we still need rigorously designed,multi-center,large-scale trials to further confirm the efficacy and safety of SZL.展开更多
基金funding support from the Major new drug creation project (2017ZX09101002-002-008)National Natural Science Foundation of China (81403171)Autonomous Program of China Academy of Chinese Medical Sciences (QZPT001 and 2014065)
文摘Objective To predict the main active ingredients,potential targets and molecular mechanisms of Yuan Zhi powder in treatment of dementia by using network pharmacology.Methods A database of chemical constituents of Yuan Zhi powder was constructed by using databases and literatures.Potential targets were predicted by reverse molecular docking,and then a component-target network was constructed.The target network of Alzheimer's disease(AD)was mapped and analyzed to obtain the“active ingredient-AD target”network.The key targets were screened through network analysis.Finally,the rationality of the prediction was analyzed by comparing with the target reported in the literatures.Results There were180chemical constituents acting on the AD target,and the targets included three key targets(cyclooxygenase-2,muscarinic acetylcholine receptor M1,and muscarinic acetylcholine receptor M2)and an important target(acetylcholine esterase).Alzheimer's disease may be treated by regulating the activity of acetylcholine receptors and the binding toβ-amyloid protein,and its biological process may be concentrated in the acetylcholine receptor signal pathway,negative regulation of synaptic transmission and so on.Conclusion The fact that Yuan Zhi powder can treat AD is consistent with the characteristics of multi-components-multitargets-multiple pathways of traditional Chinese medicine.The important targets obtained from network analysis have a large proportion in literature research,so network analysis have some rationality.
基金supported by the National Natural Science Foundation of China(No.81973825)the Natural Science Research Foundation of Anhui Province Universities(No.KJ2020A0436)。
文摘Objective:To explore and verify the mechanism of Gan Dou Ling in improving liver fibrosis in Wilson disease(WD)by network pharmacology and copper loaded mice experiments.Methods:The main chemical components and corresponding gene targets of each drug in Gan Dou Ling were obtained by using TCMSP database.The database of gene mutation and disease related gene was searched through the GeneCards database,DrugBank database,PharmGKB database and the DisGeNET database.After the intersection of drug and disease target genes.The STRING website was used to analyze the protein-protein interaction degree of target genes,and import the data to Cytoscape software 38.2 to analyze protein interaction network.The GO databases and KEGG databases were obtained in R language for enrichment analysis.On this basis,Masson staining were used to observe the degree of liver fibrosis in copper loaded mouse model,and the results of network pharmacological analysis were verified by Western Blot(WB).Results:A total of 108 drug disease intersection genes were analyzed by network pharmacology.Through PPI network analysis,JUN was found to be the key genes.The enrichment analysis of KEGG pathway showed that MAPK signal pathway was the important potential target pathways.Animal experiments showed that Gan Dou Ling could reduce liver fibrosis and inhibit the phosphorylation of P38,JNK and C-JUN in copper loaded mice.Conclusion:Gan Dou Ling may achieve the effect of treating WD liver fibrosis by inhibiting P38/JNK signaling pathway.
文摘Short Retraction Notice The paper does not meet the standards of “Chinese Medicine ". This article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE's Retraction Guidelines. The aim is to promote the circulation of scientific research by offering an ideal research publication platform with due consideration of internationally accepted standards on publication ethics. The Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused. Editor guiding this retraction: Prof. Maythem Saeed (EiC of CM) The full retraction notice in PDF is preceding the original paper, which is marked "RETRACTED".
基金This work was supported by the second batch of the“Ten thousand plan”,a national high-level talent special support plan(W02020052).
文摘Objective:To evaluate the efficacy and safety of Shen Zhi Ling oral liquid(SZL)alone or combined with basic treatment in treating Alzheimer's Disease(AD).Methods:Databases including PubMed,the Cochrane Library,Embase,Web of science,China National Knowledge Infrastructure(CNKI),Wanfang Database and the Chinese Science and Technology Journal Database(VIP)were searched from inception to September 20,2020 to collect relevant randomized controlled trials(RCTs)comparing SZL with other nootropic drugs for AD.The primary clinical outcomes were scores of the Mini Mental State Examination(MMSE)and the Activities of Daily Living(ADL)during treatment.The secondary outcomes of our study included other neuropsychological scale scores including Rapid Verbal Retrieve(RVR),Digit Span(DS),Fuld Object-Memory Evaluation(FOM)and adverse events or reactions.Two authors searched and screened the literature independently,then extracted the data and evaluated the methodological quality by using the handbook of Cochrane Collaboration,and analyzed the data via the Review Manager 5.3 software.Results:In total,we included four studies,covering 217 participants.All studies were in a low methodological quality.The result of MMSE score,ADL score,RVR score,DS score and FOM score in the meta-analysis showed that no statistically significant difference(P>0.05)between the treatment groups and control groups,and the statistical heterogeneity of all meta-analyses was small(I2<50%).SZL was indicated no better than other nootropic drugs.Among the included studies,no study described adverse events.Conclusions:Considering the low quality of the included trials and the different levels of AD patients,we are unable to come to any conclusion about the efficacy and safety of SZL compared with other nootropic drugs.Moreover,we still need rigorously designed,multi-center,large-scale trials to further confirm the efficacy and safety of SZL.
